Sodium-glucose cotransporter type 2 inhibitors: successful running after two hares
| Autor: | I. E. Mikhailova, N. B. Perepech |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
diabetes business.industry Sodium chemistry.chemical_element heart failure 030209 endocrinology & metabolism 030204 cardiovascular system & hematology 03 medical and health sciences 0302 clinical medicine Endocrinology chemistry Internal medicine RC666-701 medicine Diseases of the circulatory (Cardiovascular) system prognosis Cardiology and Cardiovascular Medicine Cotransporter business keywords: sodium-glucose cotransporter type 2 inhibitors |
| Zdroj: | Российский кардиологический журнал, Vol 26, Iss 2S (2021) |
| ISSN: | 2618-7620 1560-4071 |
| Popis: | The review is devoted to the clinical efficacy of sodium-glucose cotransporter type 2 (SGLT2) inhibitors. Information on the mechanisms of drug action is given, as well as rationale for their use in the management of patients with diabetes and heart failure (HF) is provided. The results of large-scale randomized clinical trials evaluating the efficacy of SGLT2 inhibitors are discussed. We showed the beneficial effect of SGLT-2 inhibitors on the risk of cardiovascular events in patients with type 2 diabetes. In addition, an evidence of the ability of dapagliflozin and empagliflozin to improve the prognosis of patients with HF with reduced ejection fraction without diabetes are presented. The evidence and mechanisms of the nephroprotective action of SGLT2 inhibitors in patients with diabetes and HF are considered. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|